BerGenBio to Present Company Update at DNB Nordic Healthcare Conference

26 Nov 2024 08:00 CET

BERGEN, Norway, November 26, 2024- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, announced that the Company will present at the DNB
Nordic Healthcare Conference today in Oslo, Norway at 14:45-15:05 CET.

Chief Executive Officer Olav Hellebø will provide a business update including
progress of the ongoing BGBC016 clinical study in 1st line Non-Small Cell Lung
Cancer patients with STK11 mutations.

The presentation used at the conference will be available in the investor
section of the Company's websitewww.bergenbio.com/investors/presentations at
time of the presentation.

-End-

Contacts

Olav Hellebø, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site